Great Lakes Retirement Inc. Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Great Lakes Retirement Inc. grew its position in Stryker Co. (NYSE:SYK) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,748 shares of the medical technology company’s stock after acquiring an additional 61 shares during the quarter. Great Lakes Retirement Inc.’s holdings in Stryker were worth $1,709,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Exchange Traded Concepts LLC raised its holdings in shares of Stryker by 1.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,261 shares of the medical technology company’s stock worth $1,901,000 after acquiring an additional 96 shares during the period. Koshinski Asset Management Inc. increased its position in Stryker by 4.0% during the third quarter. Koshinski Asset Management Inc. now owns 2,403 shares of the medical technology company’s stock worth $868,000 after purchasing an additional 92 shares during the last quarter. Grove Bank & Trust raised its stake in Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 56 shares during the period. CX Institutional boosted its holdings in Stryker by 3.9% in the 3rd quarter. CX Institutional now owns 3,478 shares of the medical technology company’s stock valued at $1,257,000 after purchasing an additional 130 shares during the last quarter. Finally, Wesbanco Bank Inc. grew its stake in shares of Stryker by 5.7% in the 3rd quarter. Wesbanco Bank Inc. now owns 26,172 shares of the medical technology company’s stock valued at $9,455,000 after buying an additional 1,401 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 0.5 %

SYK stock opened at $390.52 on Wednesday. The company’s 50 day moving average is $377.28 and its two-hundred day moving average is $365.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $148.88 billion, a P/E ratio of 50.33, a PEG ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company earned $3.46 earnings per share. Research analysts expect that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Barclays increased their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. UBS Group boosted their target price on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. raised their price target on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Finally, Wells Fargo & Company boosted their price objective on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.